Uitkomstenonderzoek dure geneesmiddelen. Pilot studies bortezomib en oxaliplatin: resultaten en methodologische aanbevelingen

In het kader van de NZa beleidsregels ‘Dure geneesmiddelen’ en ‘Weesgeneesmiddelen in academische ziekenhuizen’ beoordeelt het CVZ sinds 1 januari 2006 of dure geneesmiddelen tijdelijk kunnen worden opgenomen in deze beleidsregels en daarmee aanspraak maken op additionele financiering. Deze aanspraak is gekoppeld aan het verzamelen van gegevens in de klinische praktijk, het uitkomstenonderzoek. Op basis van het uitkomstenonderzoek vindt na 4 jaar een herbeoordeling plaats, waarin naast de therapeutische waarde en het kostenbeslag ook de kosteneffectiviteit wordt beoordeeld. Tot 2012 adviseerde het CVZ de NZa en VWS op basis van deze herbeoordeling over continuering van additionele financiering middels de NZa beleidsregels

Arhivske vijesti o pučkoj drami u srednjoj Dalmaciji

© 2017 Association for Computing Machinery. Context: The research literature on software development projects usually assumes that effort is a good proxy for cost. Practice, however, suggests that there are circumstances in which costs and effort should be distinguished. Objectives: We determine similarities and differences between size, effort, cost, duration, and number of defects of software projects. Method: We compare two established repositories (ISBSG and EBSPM) comprising almost 700 projects from industry. Results: We demonstrate a (log)-linear relation between cost on the one hand, and size, duration and number of defects on the other. This justifies conducting linear regression for cost. We establish that ISBSG is substantially different from EBSPM, in terms of cost (cheaper) and duration (faster), and the relation between cost and effort. We show that while in ISBSG effort is the most important cost factor, this is not the case in other repositories, such as EBSPM in which size is the dominant factor. Conclusion: Practitioners and researchers alike should be cautious when drawing conclusions from a single repository

Health related quality of life in patients with multiple myeloma undergoing a double transplantation

Objectives: To investigate the subjective well-being of patients with newly diagnosed multiple myeloma who were treated in a tandem transplantation programme. Methods: Fifty-one patients participated in the prospective, longitudinal questionnaire study. The EORTC QLQ-C30 and the EuroQol-5D were administered 2 wk after completion of vincristine, adriamycin and dexamethason/vincristine, adriamycin and methyl prednison (VAD/VAMP) chemotherapy, both at hospital discharge after treatment with high-dose melphalan (HDM) and 1 month after this hospital discharge, at hospital admission, at the day of hospital discharge for peripheral stem cell transplantation (PSCT) and at 6 and 12 months following discharge after PSCT. Results: Overall, patients' functioning improved during treatment and follow-up, with significant decreases shortly following PSCT. Shortly after HDM and PSCT, patients reported a considerable increase in levels of soreness in the mouth (+ 26/ + 36 points on a scale ranging form 0 to 100; P < 0.01), change of taste (+ 23/ + 21 points; P < 0.05/ NS), nausea/vomiting (+ 26